JPWO2022158528A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022158528A5
JPWO2022158528A5 JP2022576742A JP2022576742A JPWO2022158528A5 JP WO2022158528 A5 JPWO2022158528 A5 JP WO2022158528A5 JP 2022576742 A JP2022576742 A JP 2022576742A JP 2022576742 A JP2022576742 A JP 2022576742A JP WO2022158528 A5 JPWO2022158528 A5 JP WO2022158528A5
Authority
JP
Japan
Prior art keywords
group
pharmaceutical composition
carbon atoms
composition according
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022576742A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022158528A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/001997 external-priority patent/WO2022158528A1/ja
Publication of JPWO2022158528A1 publication Critical patent/JPWO2022158528A1/ja
Publication of JPWO2022158528A5 publication Critical patent/JPWO2022158528A5/ja
Pending legal-status Critical Current

Links

JP2022576742A 2021-01-20 2022-01-20 Pending JPWO2022158528A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021007531 2021-01-20
PCT/JP2022/001997 WO2022158528A1 (ja) 2021-01-20 2022-01-20 抗ウイルス剤

Publications (2)

Publication Number Publication Date
JPWO2022158528A1 JPWO2022158528A1 (https=) 2022-07-28
JPWO2022158528A5 true JPWO2022158528A5 (https=) 2025-01-28

Family

ID=82549509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022576742A Pending JPWO2022158528A1 (https=) 2021-01-20 2022-01-20

Country Status (8)

Country Link
US (1) US20240131046A1 (https=)
EP (1) EP4282420A4 (https=)
JP (1) JPWO2022158528A1 (https=)
KR (1) KR20230137361A (https=)
CN (1) CN116761615A (https=)
AU (1) AU2022210132A1 (https=)
CA (1) CA3206486A1 (https=)
WO (1) WO2022158528A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117820248A (zh) * 2021-04-14 2024-04-05 盐野义制药株式会社 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物
CN116782904A (zh) * 2021-09-28 2023-09-19 盐野义制药株式会社 含有三嗪衍生物的医药组合物
CA3233206A1 (en) * 2021-09-28 2023-04-06 Yuki Tachibana Pharmaceutical composition containing triazine derivative
TW202320793A (zh) * 2021-09-28 2023-06-01 日商塩野義製藥股份有限公司 含有三嗪衍生物之醫藥組合物
JP7253866B1 (ja) * 2021-11-24 2023-04-07 塩野義製薬株式会社 トリアジン誘導体を含有する経口投与する製剤
WO2023054732A2 (ja) * 2022-01-19 2023-04-06 塩野義製薬株式会社 新型コロナウイルス感染症治療用医薬
WO2024076951A2 (en) * 2022-10-04 2024-04-11 The Scripps Research Institute Antiviral prodrugs and formulations thereof
JPWO2024075794A1 (https=) * 2022-10-04 2024-04-11
CN117357531A (zh) * 2023-09-08 2024-01-09 湖北九康通生物医药有限公司 一种药物组合物、其制备方法和其应用
CN117417387A (zh) * 2023-09-13 2024-01-19 苏州翔实医药发展有限公司 一种核苷类似物的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020885A2 (en) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
US11738025B2 (en) * 2020-02-04 2023-08-29 Oyagen, Inc. Method for treating coronavirus infections
MX2022012360A (es) * 2020-04-01 2022-10-21 Union Therapeutics As Tratamiento.
KR20210151949A (ko) * 2020-04-05 2021-12-14 화이자 인코포레이티드 Covid-19의 치료를 위한 화합물 및 방법
IL297319A (en) * 2020-04-13 2022-12-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Use of metabolic regulators for the treatment of covid-19
EP3930730A4 (en) * 2020-04-15 2022-05-11 Starpharma Pty Limited PROPHYLAXIS FOR CORONAVIRUS AND/OR RESPIRATORY SYNCYTIAL VIRUS INFECTION
EP3912628A1 (en) * 2020-05-20 2021-11-24 Institut de Recherche en Semiochimie et Ethologie Appliquée Nucleoside analogues to inhibit the main protease of a coronavirus
US20220177982A1 (en) * 2020-12-03 2022-06-09 Regeneron Pharmaceuticals, Inc. Methods Of Identifying Subjects Having An Increased Risk Of Developing A Coronavirus Infection And Treatment Thereof

Similar Documents

Publication Publication Date Title
JPWO2022158528A5 (https=)
JP2010539241A5 (https=)
US9676808B2 (en) 2′,4′-substituted nucleosides as antiviral agents
JP2011521903A5 (https=)
JP2011518835A5 (https=)
RU2403258C2 (ru) Тиазолилдигидроиндазолы
RU2405774C2 (ru) Гетероциклические ингибиторы аспартилпротеазы
EP1321463B1 (en) Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections
JP2014514308A5 (https=)
ME01294B (me) Nova jedinjenja i kompozicije i metode upotrebe
JP5837936B2 (ja) アルキルスルフィニル置換チアゾリド化合物
JP2012517444A5 (https=)
RU2010112408A (ru) Фосфадиазиновые ингибиторы iv полимеразы hcv
RU2488582C2 (ru) Бициклозамещенные азопроизводные пиразолона, способ их получения и фармацевтическое применение
JP2024001048A5 (https=)
CA2490200A1 (en) 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
AR036672A1 (es) Derivados de pirrolidinona
JP2006515858A5 (https=)
RU2008119842A (ru) Производные триазола в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы-1
AR044856A1 (es) Acidos biariloximetilarenocarboxilicos; procedimientos para su preparacion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
JPWO2023106310A5 (https=)
JPWO2022251502A5 (https=)
JP2021529159A5 (https=)
JPWO2023095860A5 (https=)
JP2021510709A5 (https=)